GlobeNewswire·Mar 5, 2026, 8:00 AM ET

Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

Silexion Therapeutics Corp. will hold an Extraordinary General Meeting of Shareholders on March 16, 2026.
Shareholders will vote on an Authorized Share Capital Increase Proposal to raise the total authorized shares from 9 million to 59 million ordinary shares.
Shareholders will vote on an Equity Incentive Plan Evergreen Increase Proposal to amend the 2024 Plan, increasing the annual share addition pool to 10% of issued shares on a fully diluted basis.
The Board of Directors unanimously recommends voting FOR all proposals to support the development of lead candidate SIL-204, maintain Nasdaq compliance, & incentivize employees.
A quorum is required for the meeting to proceed, & shareholders are urged to vote via proxy card, online at cstproxyvote.com, or through their brokers.
Silexion Therapeutics is a clinical-stage oncology company focused on developing treatments for solid tumors with mutated KRAS oncogenes.
The press release includes forward-looking statements regarding clinical trials, regulatory submissions, & future capital requirements, which involve risks & uncertainties.